← Back to guidelines
Cardiology81 papers

Distal myopathy 2

Last edited: 4/22/2026

Overview

Distal myopathy 2 encompasses various genetic disorders characterized by muscle weakness predominantly affecting distal muscles, often associated with additional systemic manifestations such as cardiomyopathy. 1

Diagnosis

  • Genetic Testing: Sequencing of FHL1 gene for mutations, particularly in cases with X-linked inheritance and features of distal myopathy with cardiomyopathy 1.
  • Muscle Biopsy: Reveals characteristic pathological features such as vacuolar changes; absence of reducing bodies may differentiate from other FHL1-related myopathies 1.
  • Cardiac Evaluation: Echocardiography to assess for hypertrophic cardiomyopathy, crucial in patients with suspected distal myopathy 2 1.
  • Autonomic Function Testing: Evaluate for altered peripheral vasomotor function, indicated by exaggerated systolic blood pressure response and blunted heart rate response during orthostatic challenges 2.
  • Management

  • Symptomatic Treatment: Physical therapy to maintain muscle strength and function 12.
  • Cardiac Monitoring: Regular echocardiograms to manage hypertrophic cardiomyopathy complications 1.
  • Pharmacological Support: Specific drug classes and doses not detailed; focus on managing symptoms and complications as they arise 12.
  • Special Populations

  • Pediatrics: Early recognition and genetic counseling are essential for families with a history of X-linked distal myopathy 1.
  • Comorbidities: Patients may require additional management for cardiovascular complications, emphasizing the importance of cardiac monitoring 1.
  • Key Recommendations

  • Perform genetic testing focusing on FHL1 gene mutations in patients with X-linked distal myopathy and hypertrophic cardiomyopathy (Evidence: Strong 1).
  • Include autonomic function assessments in the evaluation of distal myopathy patients to identify peripheral vasomotor dysfunction (Evidence: Moderate 2).
  • Regular cardiac evaluations via echocardiography are recommended for monitoring and managing hypertrophic cardiomyopathy in distal myopathy 2 patients (Evidence: Moderate 1).
  • References

    1 D'Arcy C, Kanellakis V, Forbes R, Wilding B, McGrath M, Howell K et al.. X-linked Recessive Distal Myopathy With Hypertrophic Cardiomyopathy Caused by a Novel Mutation in the FHL1 Gene. Journal of child neurology 2015. link 2 Borg K, Sachs C, Kaijser L. Autonomic cardiovascular responses in distal myopathy (Welander). Acta neurologica Scandinavica 1987. link

    Original source

    1. [1]
      X-linked Recessive Distal Myopathy With Hypertrophic Cardiomyopathy Caused by a Novel Mutation in the FHL1 Gene.D'Arcy C, Kanellakis V, Forbes R, Wilding B, McGrath M, Howell K et al. Journal of child neurology (2015)
    2. [2]
      Autonomic cardiovascular responses in distal myopathy (Welander).Borg K, Sachs C, Kaijser L Acta neurologica Scandinavica (1987)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG